WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Metro North Hospital and Health Service
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Medical
HTL | March 14, 2022
HTL Biotechnology, a pioneer and world leader in the development and production of innovative pharmaceutical grade biopolymers, today announced its incubator's first equity investment in GelMEDIX Inc., an early-stage biotechnology company committed to developing the next generation of ocular and regenerative therapies. This investment supports continued development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therap...
Industrial Impact
Second Genome | March 03, 2022
Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. During the collaboration, Second Genome generated and explored environmental metagenomes that include genomic information from bacteria that are yet to be identified and cultured. Read More
Enviral Tech | August 07, 2020
Enviral Tech, a biotechnology company that provides molecular hygiene testing for the management of pandemic and post-pandemic facility safety assurance, is pleased to announce the availability of its SARS-CoV-2 (COVID-19) Surface Check and Air Check Test Kits. Available throughout the United States, the kits can be used on any surface or in any environment for early detection of the COVID-19 virus to ensure the health of communities, prevent new infection, and restore consumer confidence....
Research
Evelo Biosciences, Inc. | January 18, 2022
Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE